Sanjay Gambhir

Sanjay Gambhir

Auto-generated profile, based on publicly available information

Sanjay Gambhir

Department of Nuclear Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP, 226014, India

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SGSanjay Gambhir
Sanjay Gambhir
MRMudalsha Ravina
Mudalsha Ravina
KRKasturi Rangan
Kasturi Rangan
MDManish Dixit
Manish Dixit
SBSukanta Barai
Sukanta Barai
JBJamshed Bomanji
Jamshed Bomanji
Tuberculosis (TB) remains a major global public health problem, with 1.5 million deaths annually worldwide. One in five cases of TB present as extrapulmonary TB (EPTB), posing major diagnostic and management challenges. Mycobacterium tuberculosis adapts to a quiescent physiological state and is notable for its complex interaction with the host, producing poorly understood disease states ranging from latent infection to active clinical disease. New tools in the diagnostic armamentarium are urgently required for the rapid diagnosis of TB and monitoring of TB treatments, and to gain new insights into pathogenesis. The typical and atypical imaging features of EPTB are reviewed herein, and the roles of several imaging modalities for the diagnosis and management of EPTB are discussed.

1 April 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
DSDeepa Singh
Deepa Singh
ACAditi Chopra
Aditi Chopra
MRMudalsha Ravina
Mudalsha Ravina
SKSrikant Kongara
Srikant Kongara
EBEesh Bhatia
Eesh Bhatia
SGSanjay Gambhir
Sanjay Gambhir
Objective:The aim of this study was to evaluate the role of 68Ga-DOTANOC positron emission tomography (PET)/CT scan in localization of culprit lesion for biopsy and required intervention [surgical excision/radiofrequency ablation (RFA)] in patients with long-standing oncogenic osteomalacia (OOM)/tumour-induced osteomalacia.Methods:17 patients (8 males and 9 females) underwent 68Ga-DOTANOC PET/CT scan. The patients referred with clinical and biochemical evidence of hypophosphatemia and raised fibroblast growth factor-23. Qualitative and semi-quantitative parameters were used to identify culprit lesions.Results:68Ga-DOTANOC PET/CT scan revealed 52 lesions in 17 patients, and 37/52 of these lesions were tracer avid. 26/37 lesions were non-specific focal tracer-avid skeletal lesions (fractures or degenerative changes). 11/37 tracer-avid skeletal lesions present in 9 patients (3 lesions in 1 patient and 1 each in rest of the 8 patients) were highly suspicious for culprit lesions in view of high maximum standar...

22 December 2015 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ARAmritha Rammohan
Amritha Rammohan
GMGargi Mishra
Gargi Mishra
BMBinapani Mahaling
Binapani Mahaling
LTLokesh Tayal
Lokesh Tayal
AMAhana Mukhopadhyay
Ahana Mukhopadhyay
SSSri Sivakumar
Sri Sivakumar

1 January 2019 in Indian Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
SGSanjay Gambhir
Sanjay Gambhir
MOManish Ora
Manish Ora
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Invasive coronary angiography (ICA) is the gold standard for the evaluation of epicardial CAD. In the pathogenesis of the CAD, myocardial perfusion abnormalities are the first changes that appear followed by wall motion abnormalities, electrocardiogram changes, and angina. Myocardial perfusion imaging (MPI) demonstrates the cumulative effect of pathology at epicardial coronary arteries, small vessels, and endothelium. Thus, it evaluates the overall burden of ischemic heart disease (IHD). MPI is used noninvasively to diagnose early asymptomatic CAD or to know the functional significance of known CAD. There are evidence that early detection of myocardial perfusion abnormalities followed by aggressive intervention against cardiovascular risk factors may restore myocardial perfusion. This may lead to reduce morbidity and mortality. Various MPI modalities have been used to diagnose and define the severity of CAD. Cardiac myocardial perfusion single-photon emission computed tomography (myocardial perfusion scintigraphy [MPS]) has been in use since decades. Several newer modalities such as positron emission tomography, cardiac magnetic resonance imaging, computed tomography perfusion, and myocardial contrast echocardiography are developing utilizing the similar principle of MPS. We shall be reviewing briefly these modalities, their performance, comparison to each other, and with ICA.

2 June 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
JBJamshed Bomanji
Jamshed Bomanji
RSRajnish Sharma
Rajnish Sharma
BMBhagwant R. Mittal
Bhagwant R. Mittal
SGSanjay Gambhir
Sanjay Gambhir
AQAhmad Qureshy
Ahmad Qureshy
TPThomas N. B. Pascual
Thomas N. B. Pascual

16 November 2022 in Life
Verified
Journal Article
Open access
PDF file
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
URUpendra Rathore
Upendra Rathore
PMPrabhaker Mishra
Prabhaker Mishra
KSKritika Singh
Kritika Singh
DTDarpan R. Thakare
Darpan R. Thakare
VAVikas Agarwal
Vikas Agarwal
Takayasu arteritis (TAK) could cause a stroke or transient ischemic attack (TIA) in young individuals due to inflammatory vascular occlusion or intracerebral hemorrhage. We compared the clinical presentation, angiographic features, longitudinal patterns of disease activity, medical treatments, and survival in 34 TAK patients with stroke/TIA and 157 without stroke/TIA from a single-center retrospective cohort. TAK patients with stroke/TIA were older (p = 0.044) with a greater proportion of males (p = 0.022), more frequent vision loss (odds ratio (OR) for stroke/TIA vs. without stroke TIA 5.21, 95% CI 1.42–19.14), and less frequent pulse or blood pressure inequality (OR 0.43, 95% CI 0.19–0.96) than TAK patients without stroke/TIA. Hata’s angiographic type IIa was more common in TAK patients with stroke/TIA (OR 11.00, 95%CI 2.60–46.58) and type V in TAK patients without stroke/TIA (OR 0.27, 95% CI 0.12–0.58). Cyclophosphamide was used more often in TAK patients with stroke/TIA (p = 0.018). Disease activity at baseline, 6, 12, and 24 months of follow-up was mostly similar for both groups. Risk of mortality was similar in TAK patients with or without stroke/TIA (hazard ratio unadjusted 0.76, 95% CI 0.15–3.99; adjusted for gender, age of disease onset, delay to diagnosis, baseline disease activity, and the number of conventional or biologic/targeted synthetic immunosuppressants used 1.38, 95% CI 0.19–10.20) even after propensity score-matched analyses. Stroke or TIA does not appear to affect survival in TAK patients adversely.